Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) EBIT Margin (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed EBIT Margin for 9 consecutive years, with 6932.81% as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, EBIT Margin fell 559166.0% year-over-year to 6932.81%, compared with a TTM value of 34632.29% through Sep 2025, down 2696632.0%, and an annual FY2024 reading of 15535.6%, down 1411403.0% over the prior year.
  • EBIT Margin was 6932.81% for Q4 2024 at Avalo Therapeutics, down from 5165.06% in the prior quarter.
  • Across five years, EBIT Margin topped out at 27.39% in Q3 2022 and bottomed at 8202.28% in Q4 2021.
  • Average EBIT Margin over 5 years is 2365.78%, with a median of 1207.27% recorded in 2020.
  • The sharpest move saw EBIT Margin tumbled -711052bps in 2021, then skyrocketed 721411bps in 2022.
  • Year by year, EBIT Margin stood at 1091.76% in 2020, then tumbled by -651bps to 8202.28% in 2021, then skyrocketed by 88bps to 988.17% in 2022, then crashed by -36bps to 1341.16% in 2023, then crashed by -417bps to 6932.81% in 2024.
  • Business Quant data shows EBIT Margin for AVTX at 6932.81% in Q4 2024, 5165.06% in Q3 2024, and 1341.16% in Q4 2023.